CSPC Megalith Biopharmaceutical Co., Ltd. was founded in 2019 and is located in Shijiazhuang International Biomedical Industry Park. In accordance with international high standards, the company has built a high-tech industrialization base for innovative biopharmaceuticals with independent intellectual property rights, focusing on the R&D, production and sales of biological drugs. It serves as a core carrier for CSPC Pharmaceutical Group to translate innovative drug discovery from early-stage R&D into large-scale commercial production. The company has launched China’s first mRNA vaccine on the market.The company boasts five well-established technological platforms, namely mRNA vaccine development, antibody engineering optimization, phage and yeast display, enzymatic site-specific modification, and nano-delivery. Focusing on three major therapeutic areas—severe infectious diseases, malignant tumors, and autoimmune diseases—the company is capable of supporting the R&D and commercial production of macromolecular protein drugs and nucleic acid drugs.

At present, an mRNA vaccine production line with an annual output of 1.5 billion doses has been completed, equipping the company with full-fledged core technical capabilities for mRNA vaccine development. All technologies concerning vaccine design, R&D and manufacturing are independently developed. The company’s novel coronavirus mRNA vaccine project has achieved breakthrough progress, making it the first domestically marketed mRNA vaccine in China.

The company’s production lines feature a high level of informatization and automation, incorporating information systems such as MES, LIMS, WMS, SAP and SMR to generate a full range of data reports. This highly informatized and automated design not only reduces workers’ labor intensity, but also enhances production efficiency.